Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.
about
Development of topical microbicides to prevent the sexual transmission of HIVHistorical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulationsFormulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product.Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory.Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation.Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial designQuantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: implications for microbicide development.Vaginal drug delivery systems for HIV prevention.Pharmaceutical development of microbicide drug products.Considerations in developing a target product profile for parenteral pharmaceutical products.Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.Preparation of multiparticulate vaginal tablet using glyceryl monooleate for sustained progesterone delivery.Vaginal distribution and retention of tablets comprising starch-based multiparticulates: evaluation by colposcopy.Advanced preformulation investigations for the development of a lead intravaginal bioadhesive polymeric deviceVaginal Mucosa and Drug Delivery
P2860
Q33625073-A2DD8320-02A2-4ECF-B49F-88C9F9AF9171Q33821090-3C14A294-8B78-46BC-B148-0E3D2EAF7B4DQ34309533-8F5D7AF1-1B2C-4994-A2E9-BC92E71FBDF7Q34704317-9604EAAD-16B8-4C44-87CB-D175750ECDBBQ34932706-37138673-549E-4BB6-9841-80E92E11697DQ35012298-B936D626-D21B-4B69-ABFB-8AD5538126B3Q36096590-1B0FF723-1259-4BDC-9637-3900895E2F49Q36343077-E2FBEDA0-3221-470D-A486-B02E05A39B07Q36425572-08571529-119C-4443-A05D-47A758364F02Q37149107-5C66F30F-3FF4-4E03-8582-C8D02B1453C0Q37657468-D2866BAE-AC53-4870-97A9-D32CAEEF15DFQ37788992-2AEBB3C1-4304-4E04-BE68-5B1625F6E77DQ41140055-04315938-D9C3-43CC-97AA-FA73639B7231Q46358491-2D35BEBA-09EB-40B9-B34A-70267F0F2C33Q49153215-DCE88448-9D68-4EB4-9C55-776BE9B3AF95Q57382770-D02A6474-7DA1-4F40-BB61-1A25A5F3423EQ57570821-8D7EF56E-AC25-4448-BF80-6FD97031820D
P2860
Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development pharmaceutics of m ...... n, evaluation, and challenges.
@ast
Development pharmaceutics of m ...... n, evaluation, and challenges.
@en
type
label
Development pharmaceutics of m ...... n, evaluation, and challenges.
@ast
Development pharmaceutics of m ...... n, evaluation, and challenges.
@en
prefLabel
Development pharmaceutics of m ...... n, evaluation, and challenges.
@ast
Development pharmaceutics of m ...... n, evaluation, and challenges.
@en
P2093
P1476
Development pharmaceutics of m ...... n, evaluation, and challenges.
@en
P2093
Donald P Waller
Kaustubh R Tambwekar
Kavita Vermani
Lourens J D Zaneveld
Raghupathi Kandarapu
Sanjay Garg
P304
P356
10.1089/108729103322277402
P577
2003-08-01T00:00:00Z